Literature DB >> 3104057

One year study of effects of an oestrogen-dominant oral contraceptive on serum high-density lipoprotein cholesterol, apolipoproteins A-I and A-II and hepatic microsomal function.

P V Luoma, J E Heikkinen, C Ehnholm, P R Ylöstalo.   

Abstract

The effects over 1 year of an oestrogen-dominant oral contraceptive containing ethinylestradiol and levonorgestrel on serum high-density lipoprotein cholesterol, apolipoproteins A-I and A-II and liver microsomal enzyme activity assessed by antipyrine kinetics, were investigated in 21 healthy, young women. HDL cholesterol and apolipoprotein concentrations rose and hepatic microsomal enzyme activity fell during the first month of the treatment, and remained affected throughout the year. After discontinuation of treatment, the lipid and apolipoprotein concentrations and the microsomal enzyme activity returned to their pretreatment levels within 1 month. The drug, by reducing hepatic enzyme activity, may have influenced both the antipyrine elimination rate and the high-density lipoprotein concentration.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3104057     DOI: 10.1007/bf00606631

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  24 in total

1.  The antipyrine test in clinical pharmacology: conceptions and misconceptions.

Authors:  E S Vesell
Journal:  Clin Pharmacol Ther       Date:  1979-09       Impact factor: 6.875

2.  Effect of moderate physical exercise on serum lipoproteins. A controlled clinical trial with special reference to serum high-density lipoproteins.

Authors:  J K Huttunen; E Länsimies; E Voutilainen; C Ehnholm; E Hietanen; I Penttilä; O Siitonen; R Rauramaa
Journal:  Circulation       Date:  1979-12       Impact factor: 29.690

3.  Metabolic regulation of plasma high density lipoprotein concentrations.

Authors:  E A Nikkila
Journal:  Eur J Clin Invest       Date:  1978-06       Impact factor: 4.686

4.  Effects of medroxyprogesterone on the liver function and drug metabolism of patients with primary biliary cirrhosis and chronic active hepatitis.

Authors:  E A Sotaniemi; T Hynnynen; J Ahlqvist; J T Ahokas; U Puoskari; I Pelkonen
Journal:  J Med       Date:  1978

5.  Localization of the heparin-releasable lipase in situ in the rat liver.

Authors:  T Kuusi; E A Nikklä; I Virtanen; P K Kinnunen
Journal:  Biochem J       Date:  1979-07-01       Impact factor: 3.857

6.  Fasting serum triglyceride, cholesterol, and lipoprotein levels during oral-contraceptive therapy.

Authors:  V Wynn; G L Mills; J W Doar; T Stokes
Journal:  Lancet       Date:  1969-10-11       Impact factor: 79.321

7.  Inhibition of drug metabolism. V. Inhibition of drug metabolism by steroids.

Authors:  T R Tephly; G J Mannering
Journal:  Mol Pharmacol       Date:  1968-01       Impact factor: 4.436

8.  Plasma high-density lipoprotein cholesterol and hepatic cytochrome P-450 concentrations in epileptics undergoing anticonvulsant treatment.

Authors:  P V Luoma; E A Sotaniemi; R O Pelkonen; V V Myllylä
Journal:  Scand J Clin Lab Invest       Date:  1980-04       Impact factor: 1.713

9.  Risk of myocardial infarction in relation to current and discontinued use of oral contraceptives.

Authors:  D Slone; S Shapiro; D W Kaufman; L Rosenberg; O S Miettinen; P D Stolley
Journal:  N Engl J Med       Date:  1981-08-20       Impact factor: 91.245

10.  High density lipoprotein-2 and hepatic lipase: reciprocal changes produced by estrogen and norgestrel.

Authors:  M J Tikkanen; E A Nikkilä; T Kuusi; S U Sipinen
Journal:  J Clin Endocrinol Metab       Date:  1982-06       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.